TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Opioid Treatment: Human Experimental Research
Brief Summary: Children born to women who abuse drugs have a high risk of being born with birth defects and developmental problems. Methadone is a drug that is commonly used for treating opioid dependence. However, its use by a pregnant woman can cause severe withdrawal symptoms in a newborn because of the prenatal exposure. The purpose of this study is to evaluate the effectiveness of buprenorphine, another drug, versus methadone in reducing withdrawal symptoms in children born to opioid-dependent women.


Options:
A: Arm Label: Methadone maintained lactating women; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A
C: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
D: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
Brief Summary: The effect of long term inhalation of hypertonic saline in subjects with cystic fibrosis on lung function, incidence of respiratory tract infections, quality of life, quantitative microbiology and sputum cytokine profile. The hypothesis is that regular inhalation of nebulised hypertonic saline will have a beneficial effect on lung function and other clinical outcomes with no adverse effects on infection and inflammation in adults and children with cystic fibrosis.


Options:
A: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Active Treatment Group 7% Hypertonic Saline | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control Group 0.9% Isotonic Saline | Intervention Type: DRUG; Name: Active Treatment Group 7% Hypertonic Saline; Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: Control Group 0.9% Isotonic Saline; Assigned to Arm(s): Control Group
B: Arm Label: Hypertonic saline; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic Saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hypertonic Saline; Assigned to Arm(s): Hypertonic saline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control Group
D: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
Brief Summary: The effect of long term inhalation of hypertonic saline in subjects with cystic fibrosis on lung function, incidence of respiratory tract infections, quality of life, quantitative microbiology and sputum cytokine profile. The hypothesis is that regular inhalation of nebulised hypertonic saline will have a beneficial effect on lung function and other clinical outcomes with no adverse effects on infection and inflammation in adults and children with cystic fibrosis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
C: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
D: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
Brief Summary: The effect of long term inhalation of hypertonic saline in subjects with cystic fibrosis on lung function, incidence of respiratory tract infections, quality of life, quantitative microbiology and sputum cytokine profile. The hypothesis is that regular inhalation of nebulised hypertonic saline will have a beneficial effect on lung function and other clinical outcomes with no adverse effects on infection and inflammation in adults and children with cystic fibrosis.


Options:
A: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
B: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
C: Arm Label: HS/sham; Type: EXPERIMENTAL; Interventions: Drug: inhaled hypertonic saline (7%) | Arm Label: sham/HS; Type: EXPERIMENTAL; Interventions: Drug: inhaled hypertonic saline (7%) | Intervention Type: DRUG; Name: inhaled hypertonic saline (7%); Assigned to Arm(s): HS/sham, sham/HS
D: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1% | Arm Label: group B; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%; Assigned to Arm(s): group A | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7%; Assigned to Arm(s): group B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
Brief Summary: The effect of long term inhalation of hypertonic saline in subjects with cystic fibrosis on lung function, incidence of respiratory tract infections, quality of life, quantitative microbiology and sputum cytokine profile. The hypothesis is that regular inhalation of nebulised hypertonic saline will have a beneficial effect on lung function and other clinical outcomes with no adverse effects on infection and inflammation in adults and children with cystic fibrosis.


Options:
A: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2
C: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
D: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
Brief Summary: The effect of long term inhalation of hypertonic saline in subjects with cystic fibrosis on lung function, incidence of respiratory tract infections, quality of life, quantitative microbiology and sputum cytokine profile. The hypothesis is that regular inhalation of nebulised hypertonic saline will have a beneficial effect on lung function and other clinical outcomes with no adverse effects on infection and inflammation in adults and children with cystic fibrosis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline 6% - | Intervention Type: DRUG; Name: Hypertonic saline 6% -; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception
Brief Summary: Objective: To compare the efficacy, safety and tolerance of a 50 mg dose of a new antiprogestin, CDB-2914 with a 0.75 mg bid dose of levonorgestrel as emergency contraception

Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception

Subjects are randomized to receive a one-time treatment with either one dose of 50 mg CDB-2914 (followed 12 hours later by a placebo) or 2 doses of 0.75 mg of levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed)

The primary aim is to evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel.


Options:
A: Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: levonorgestrel; Assigned to Arm(s): N/A
B: Arm Label: CDB-2914; Type: EXPERIMENTAL; Interventions: Drug: CDB-2914 | Arm Label: Levonorgestrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levonorgestrel | Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): CDB-2914 | Intervention Type: DRUG; Name: Levonorgestrel; Assigned to Arm(s): Levonorgestrel
C: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A
D: Arm Label: Copper IUD; Type: N/A; Interventions: Drug: Copper IUD | Arm Label: Levonorgestrel IUD; Type: N/A; Interventions: Drug: Levonorgestrel IUD | Intervention Type: DRUG; Name: Copper IUD; Assigned to Arm(s): Copper IUD | Intervention Type: DRUG; Name: Levonorgestrel IUD; Assigned to Arm(s): Levonorgestrel IUD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception
Brief Summary: Objective: To compare the efficacy, safety and tolerance of a 50 mg dose of a new antiprogestin, CDB-2914 with a 0.75 mg bid dose of levonorgestrel as emergency contraception

Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception

Subjects are randomized to receive a one-time treatment with either one dose of 50 mg CDB-2914 (followed 12 hours later by a placebo) or 2 doses of 0.75 mg of levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed)

The primary aim is to evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel.


Options:
A: Arm Label: CDB-2914; Type: EXPERIMENTAL; Interventions: Drug: CDB-2914 | Arm Label: Levonorgestrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levonorgestrel | Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): CDB-2914 | Intervention Type: DRUG; Name: Levonorgestrel; Assigned to Arm(s): Levonorgestrel
B: Arm Label: Copper IUD; Type: N/A; Interventions: Drug: Copper IUD | Arm Label: Levonorgestrel IUD; Type: N/A; Interventions: Drug: Levonorgestrel IUD | Intervention Type: DRUG; Name: Copper IUD; Assigned to Arm(s): Copper IUD | Intervention Type: DRUG; Name: Levonorgestrel IUD; Assigned to Arm(s): Levonorgestrel IUD
C: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: levonorgestrel; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)
Brief Summary: This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims:

1. To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status,
2. To study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and
3. To examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.


Options:
A: Arm Label: ICU Diaries; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary | Arm Label: Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation | Arm Label: ICU Diary plus Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary, Behavioral: Psychoeducation | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ICU Diary; Assigned to Arm(s): ICU Diaries, ICU Diary plus Psychoeducation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): ICU Diary plus Psychoeducation, Psychoeducation
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Problem Solving Treatment; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2
C: Arm Label: Melatonin (N-acetyl-5-methoxytryptamine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin (N-acetyl-5-methoxytryptamine) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin (N-acetyl-5-methoxytryptamine); Assigned to Arm(s): Melatonin (N-acetyl-5-methoxytryptamine) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Citalopram; Type: EXPERIMENTAL; Interventions: Drug: 20mg daily citalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 20mg daily citalopram; Assigned to Arm(s): Citalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Informatics for Diabetes Education and Telemedicine (IDEATel)
Brief Summary: The IDEATel study is a multicenter randomized controlled trial to evaluate the efficacy, acceptability, and cost-effectiveness of telemedicine case management to provide diabetes care to elderly Medicare beneficiaries residing in medically underserved areas of New York State.


Options:
A: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: VISITS + PDA-FIT system | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: PDA-FIT System + telephone follow-up | Intervention Type: DEVICE; Name: placebo; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: VISITS + PDA-FIT system; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: PDA-FIT System + telephone follow-up; Assigned to Arm(s): 3
C: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care
D: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Informatics for Diabetes Education and Telemedicine (IDEATel)
Brief Summary: The IDEATel study is a multicenter randomized controlled trial to evaluate the efficacy, acceptability, and cost-effectiveness of telemedicine case management to provide diabetes care to elderly Medicare beneficiaries residing in medically underserved areas of New York State.


Options:
A: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TM; Type: EXPERIMENTAL; Interventions: Other: Telemonitoring | Intervention Type: OTHER; Name: Telemonitoring; Assigned to Arm(s): TM
B: Arm Label: A, 1, I; Type: EXPERIMENTAL; Interventions: Device: Home blood pressure tele-management system. | Arm Label: A, 2, I; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care. | Intervention Type: DEVICE; Name: Home blood pressure tele-management system.; Assigned to Arm(s): A, 1, I | Intervention Type: OTHER; Name: Usual care.; Assigned to Arm(s): A, 2, I
C: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
D: Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Other: Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital; Assigned to Arm(s): telemedicine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Informatics for Diabetes Education and Telemedicine (IDEATel)
Brief Summary: The IDEATel study is a multicenter randomized controlled trial to evaluate the efficacy, acceptability, and cost-effectiveness of telemedicine case management to provide diabetes care to elderly Medicare beneficiaries residing in medically underserved areas of New York State.


Options:
A: Intervention Type: BEHAVIORAL; Name: personal feedback report; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: OneTouch(r) UltraSmart(r); Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
D: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Procalcitonin and Survival Study - A Multicentre Single Blinded Randomized Controlled Trial to Investigate if Treatment Guided by Daily Procalcitonin Measurements Can Reduce Mortality in the Intensive Care Unit
Brief Summary: This is a randomised, single blinded, multicentre trial to evaluate whether daily procalcitonin (PCT) measurements and immediate diagnostic and therapeutic responses to abnormal values and day-to-day changes can reduce the mortality of critically ill patients in the Intensive Care Unit (ICU).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
B: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
C: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
D: N/A

Answer: C